Wegovy Tablets Results: What the OASIS Trials Show
A realistic look at expected timelines, early changes, and what can affect progress for Wegovy Tablets Results: What the OASIS Trials Show.
Wegovy Tablets Results: What the OASIS Trials Show
The conversation around weight management is evolving, with new treatments offering more options than ever before. For years, Wegovy has been known as a once-weekly injectable medication. Now, clinical trials have explored a new form: a daily oral tablet containing the same active ingredient, semaglutide.
This shift from an injection to a pill has generated a lot of questions, especially about results. How effective is the tablet? How quickly does it work? To answer these, we can look directly at the data from the major clinical trial program, known as OASIS. This article provides a clear, realistic look at the weight loss timeline shown in these studies. Consult your healthcare provider before starting any medication.
What Were the OASIS Trials?
Before diving into the results, it’s helpful to understand where the information comes from. The OASIS (Oral Semaglutide Treatment Effect in People with Obesity) program is a series of large-scale clinical trials designed to evaluate the safety and effectiveness of a 50 mg oral semaglutide tablet for chronic weight management.
The key study, OASIS 1, involved thousands of adults with obesity or overweight who also had at least one weight-related health condition but did not have type 2 diabetes. The trial ran for 68 weeks (about 15 and a half months).
It's crucial to note that this wasn't just about taking a pill. Every participant in the trial, including those who received a placebo, also received counseling on lifestyle changes. This included guidance on a reduced-calorie diet and increased physical activity. The results reflect the combination of the medication and these important lifestyle efforts.
A Realistic Timeline for Wegovy Tablet Results
The OASIS 1 trial provides a detailed map of what to expect over time. Weight loss is a gradual process, and the study shows a clear pattern of steady progress rather than an overnight transformation.
Early Weeks: The Titration Period
Treatment with medications like semaglutide typically begins with a process called titration. This means you start on a low dose, which is gradually increased over the first few months. The primary goal of this period is to help your body adjust to the medication and minimize potential side effects, such as nausea or other gastrointestinal discomfort.
During these initial weeks, many people begin to notice the first effects of the medication, primarily a reduction in appetite and an increased feeling of fullness after meals. While some weight loss may occur during this phase, the most significant changes are usually yet to come. The focus is on consistency and establishing a routine.
The First Three Months (to Week 20)
As the dose is gradually optimized, weight loss tends to become more consistent. By the 20-week mark of the OASIS 1 trial, participants taking oral semaglutide had achieved a meaningful reduction in their body weight.
This phase is often highly motivating as the combined effects of the medication and lifestyle adjustments start to produce visible results. The early changes in appetite and fullness translate into consistent, measurable progress on the scale. It's a period where new, healthier habits begin to feel more established.
Reaching the Mid-Point (to Week 40)
By the middle of the trial, participants continued to see steady weight loss. The journey of chronic weight management is a marathon, not a sprint, and the data reflects this. The progress seen in the first few months builds, leading to more substantial health and wellness improvements.
At this stage, many participants in the trial would have experienced significant reductions not just in weight, but also in related health markers like waist circumference. This sustained progress underscores the importance of sticking with the treatment plan long-term.
The Full Study Duration (68 Weeks)
The headline result from the OASIS 1 trial came at its conclusion after 68 weeks. Participants who took the 50 mg oral semaglutide tablet, in combination with lifestyle intervention, achieved an average weight loss of 15.1% of their initial body weight.
To put that in perspective, a person weighing 230 pounds at the start of the study would have lost, on average, about 35 pounds.
Just as importantly, the group receiving a placebo (a pill with no active ingredient) alongside the same lifestyle counseling lost an average of 2.4% of their body weight. The significant difference between the two groups demonstrates the powerful effect of the medication when added to diet and exercise. Furthermore, about 85% of those taking the tablet lost 5% or more of their body weight, a level considered clinically significant for improving health.
Beyond the Pill: What Affects Your Progress?
The OASIS trial results are averages, and individual experiences will always vary. Several factors play a critical role in how successful treatment can be.
The Role of Lifestyle Changes
It cannot be overstated: the medication is a tool, not a replacement for healthy habits. The success seen in the OASIS trials was achieved by people who were also working to improve their diet and increase their physical activity. The tablet helps make these changes more manageable by regulating appetite and promoting satiety, but the commitment to a healthier lifestyle remains fundamental.
Consistency is Key
Oral semaglutide is designed to be taken once a day. The instructions typically specify taking it on an empty stomach with a small amount of water and then waiting at least 30 minutes before eating, drinking, or taking other oral medications. Adhering to this routine consistently is essential for ensuring the medication is properly absorbed and can work effectively.
Your Individual Health Profile
Everyone’s body is different. Factors like your starting weight, your unique metabolism, and the presence of other health conditions can influence your weight loss journey. Progress may be faster for some and slower for others, and that’s perfectly normal. The key is to focus on your personal trend of progress in consultation with your healthcare team.
Putting It All Together: A Long-Term Perspective
The OASIS trials show that the oral tablet version of Wegovy can lead to significant, clinically meaningful weight loss over the long term. The results unfold gradually, with progress building steadily over more than a year.
The journey begins with an adjustment period, followed by consistent weight loss that, for the average participant in the trial, culminated in a 15.1% reduction in body weight after 68 weeks. This success was achieved through a powerful partnership: the medication supporting the body, and the individual committing to durable lifestyle changes.
Ultimately, this treatment represents another valuable option in the toolkit for chronic weight management, helping individuals achieve their health goals as part of a comprehensive plan. Consult your healthcare provider before starting any medication.
Sources
- Novo Nordisk. (2023, May 22). Novo Nordisk A/S: Oral semaglutide 50 mg for obesity reduces body weight by 15% in the OASIS 1 trial [Press release]. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166115
- Khera, R., & D'Silva, K. M. (2023). Oral Semaglutide for the Treatment of Obesity. JAMA, 330(5), 425–426. https://jamanetwork.com/journals/jama/article-abstract/2807310
- Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral semaglutide 50 mg for the treatment of adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01185-6/fulltext
- National Institute of Diabetes and Digestive and Kidney Diseases. (2022). Prescription Medications to Treat Overweight & Obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
- U.S. National Library of Medicine. (2024). A Research Study to See How Well Oral Semaglutide Works in People With Overweight or Obesity (OASIS 1). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05035046
Written by
Dietician / Nutritionist
Health Content Writer
Neha Kumari is a Dietician / Nutritionist professional who contributes evidence-informed health and wellness content for WeightEasy.
View profile →Reviewed by
Immunobiologist
Senior Medical Reviewer
Dr kshama jain is a Immunobiologist professional who reviews WeightEasy health content for medical and editorial accuracy.
View profile →